OCULAR THERAPEUTIX, INC OCUL
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
3.49
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $52.0M | -$265.9M | — | -$216.9M | $654.3M |
| 2024 | $63.7M | -$193.5M | — | -$136.0M | $315.3M |
| 2023 | $58.4M | -$80.7M | — | -$76.3M | $91.1M |
| 2022 | $51.5M | -$71.0M | — | -$63.3M | $35.4M |
| 2021 | $43.5M | -$6.6M | — | -$66.7M | $88.0M |
| 2020 | $17.4M | -$155.6M | — | -$54.4M | $76.1M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 3.49 (safe)
- Working capital / assets 0.905
- Retained earnings / assets -1.432
- EBIT / assets -0.334
- Equity / liabilities 4.256
Source: SEC EDGAR filings · CIK 0001393434 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.